文献速递临床试验与 GCP

替罗非班对比阿司匹林治疗串联病变急性缺血性卒中血管内治疗再通的多中心开放随机对照临床试验(ATILA试验)的统计分析计划

Statistical analysis plan for the multicenter, open, randomized controlled clinical trial to assess the efficacy and safety of intravenous tirofiban vs aspirin in acute ischemic stroke due to tandem lesion, undergoing recanalization therapy by endovascular treatment (ATILA trial).
PubMed 文献 · Trials · 2024-01-09

ATILA试验为多中心、前瞻性、开放、评估者盲的随机对照试验,计划入组240例串联病变急性缺血性卒中行机械取栓加颈动脉支架置入的患者,按1:1随机接受静脉替罗非班或静脉阿司匹林。主要疗效结局为术后24小时内颈动脉支架内血栓形成比例,主要安全性结局为症状性颅内出血率,随访3个月。

要点

  • ATILA试验计划入组240例串联病变急性缺血性卒中行机械取栓加颈动脉支架置入的患者,每组120例。
  • 静脉阿司匹林为500毫克单次给药,替罗非班为500微克负荷后200微克/小时输注24小时。
  • 主要疗效结局为术后24小时内颈动脉支架内血栓形成比例,主要安全性结局为症状性颅内出血率。

核心结论

  • 本试验将是首个评估串联病变患者机械取栓后避免支架内血栓形成的最佳抗血小板治疗的临床试验。

研究设计与样本

  • 多中心、前瞻性、随机、对照(阿司匹林组)、评估者盲的临床试验,计划入组240例患者,每个治疗组120例。
  • 符合纳入标准的患者在机械取栓开始时按1:1随机分配至试验组或对照组。
  • 静脉阿司匹林为500毫克单次给药;替罗非班为500微克负荷后200微克/小时输注,持续24小时。
  • 所有患者随访长达3个月。

关键数值与推荐

  • 主要疗效结局为机械取栓后24小时内颈动脉支架内血栓形成的患者比例。
  • 主要安全性结局为症状性颅内出血率。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE: In-stent reocclusion after endovascular therapy has a negative impact on outcomes in acute ischemic stroke (AIS) due to tandem lesions (TL). Optimal antiplatelet therapy approach in these patients to avoid in-stent reocclusion is yet to be elucidated. AIMS: To assess efficacy and safety of intravenous tirofiban versus intravenous aspirin in patients undergoing MT plus carotid stenting in the setting of AIS due to TL. SAMPLE SIZE ESTIMATES: Two hundred forty patients will be enrolled, 120 in every treatment arm. METHODS AND DESIGN: A multicenter, prospective, randomized, controlled (aspirin group), assessor-blinded clinical trial will be conducted. Patients fulfilling the inclusion criteria will be randomized at MT onset to the experimental or control group (1:1). Intravenous aspirin will be administered at a 500-mg single dose and tirofiban at a 500-mcg bolus followed by a 200-mcg/h infusion during the first 24 h. All patients will be followed for up to 3 months. STUDY OUTCOMES: Primary efficacy outcome will be the proportion of patients with carotid in-stent thrombosis within the first 24 h after MT. Primary safety outcome will be the rate of symptomatic intracranial hemorrhage. DISCUSSION: This will be the first clinical trial to assess the best antiplatelet therapy to avoid in-stent thrombosis after MT in patients with TL. TRIAL REGISTRATION: The trial is registered as NCT05225961. February, 7th, 2022.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Zapata-Arriaza E, Medina-Rodríguez M, Moniche Álvarez F, et al. Statistical analysis plan for the multicenter, open, randomized controlled clinical trial to assess the efficacy and safety of intravenous tirofiban vs aspirin in acute ischemic stroke due to tandem lesion, undergoing recanalization therapy by endovascular treatment (ATILA trial). Trials. 2024. PMID: 38195586. doi:10.1186/s13063-023-07817-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。